year 19, Issue 73 (3-2020)                   J. Med. Plants 2020, 19(73): 12-26 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mohammadi S M, kianbakht S, Rezazadeh S, Ziaee M, Fallah Huseini H. Clinical efficacy of Silybum marianum seed extract in treatment of type 2 diabetes mellitus and non-alcoholic fatty liver disease: a narrative review. J. Med. Plants 2020; 19 (73) :12-26
1- Department of Internal Medicine, Shahid Sadoughi University of Medical Science, Yazd, Iran
2- Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran
3- Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4- Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran ,
Abstract:   (3230 Views)
Background: Several clinical studies have been undertaken to investigate the potential therapeutic effects of Silybum marianum (S. marianum) seed extract (silymarin) in Type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD). Objective: We performed the present narrative review to evaluate the efficacy of silymarin supplement for treatment of T2DM and NAFLD. Methods: Electronic databases PubMed, Science Direct, Scopus, Google and Google Scholar were surveyed for the English and non-English human clinical trial papers published concerning the effects of silymarin on T2DM and NAFLD from January 2010 to April 2018. Results: Sixteen articles regarding silymarin effects on T2DM and NAFLD in clinical studies have been included in this review. The anti-diabetic effect of silymarin was reported in four clinical trials in single formula and in one trial in combination with nettle and boswellia gum resin. The efficacy of silymarin or silybin has been reported in the treatment of NAFLD in eleven clinical trials as single formula or in combination with phosphatidylcholine, simvastatin and vitamin E. Conclusion: Silymarin appears to be effective as an adjuvant with the standard therapy in the treatment of T2DM and NAFLD.
Full-Text [PDF 617 kb]   (1597 Downloads)    
Type of Study: Review | Subject: Pharmacology & Toxicology
Received: 2018/10/23 | Accepted: 2019/03/10 | Published: 2020/06/6

1. Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, Cavan D, Shaw JE and Makaroff LE. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res. Clin. Pract. 2017; 128: 40-50. [DOI:10.1016/j.diabres.2017.03.024]
2. Marjot T, Sbardella E, Moolla A, Hazlehurst J, Tan G, Ainsworth M, Cobbold J and Tomlinson J. Prevalence and severity of non‐alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital. Diabetic Medicine. 2018; 35 (1): 89-98. [DOI:10.1111/dme.13540]
3. Armstrong MJ, Hazlehurst JM, Parker R, Koushiappi E, Mann J and Khan S. Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management. QJM. 2014; 107: 33-41. [DOI:10.1093/qjmed/hct198]
4. Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB and Therneau T. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am. J. Gastroenterol. 2010; 105:1567-73. [DOI:10.1038/ajg.2010.18]
5. Williamson RM, Price JF, Glancy S, Perry E, Nee LD and Hayes PC. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011; 34: 1139-44. [DOI:10.2337/dc10-2229]
6. Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C, Finch J, Gastaldelli A, Harrison S and Tio F. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatol. 2012; 55: 1389-1397. [DOI:10.1002/hep.25539]
7. Adams LA, Waters OR, Knuiman MW, Elliott RR and Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: An Eleven-Year Follow-up Study. Am. J. Gastroenterol. 2009; 104: 861-7. [DOI:10.1038/ajg.2009.67]
8. Tailleux A, Wouters K and Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. Biochim. Biophys. Acta. 2012; 1821 (5): 809-18. [DOI:10.1016/j.bbalip.2011.10.016]
9. Philippe J and Raccah D. Treating type 2 diabetes: how safe are current therapeutic agents? Int. J. Clin. Pract. 2009; 63 (2): 321-332. [DOI:10.1111/j.1742-1241.2008.01980.x]
10. Clarke TC, Black LI, Stussman BJ, Barnes PM and Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002-2012. Natl. Health Stat Report. 2015; 79: 1-16.
11. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front. Pharmacol. 2014; 4: 1-10. [DOI:10.3389/fphar.2013.00177]
12. Suksomboon N, Nalinee Poolsup N, Sukamai Boonkaew S, Chuthamanee C and Suthisisang C. Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes. J. Ethnopharmacol. 2011; 137: 1328- 1333. [DOI:10.1016/j.jep.2011.07.059]
13. Jacobs BP, Dennehy C, Ramirez G, Sapp J and Lawrence VA. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am. J. Med. 2002; 113: 506-515. [DOI:10.1016/S0002-9343(02)01244-5]
14. Mozaffarian V. A dictionary of Iranian Plant Names (3ed.). Farhang Moaser Press. Iran. 2003, pp: 59-60.
15. Ghahreman A. Flora of Iran. Research Institute of Forests Rangelands, Tehran, Iran. 2000, Vol. 3, pp: 587.
16. Federico A, Dallio M and Loguercio C. Silymarin/silybin and chronic liver disease: a marriage of many years. Molecules. 2017; 22 (2): 191. [DOI:10.3390/molecules22020191]
17. Hussain SA. Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes. J. Med. Food. 2007; 10 (3): 543-7. [DOI:10.1089/jmf.2006.089]
18. Trappoliere M, Caligiuri A, Schmid M, Bertolani C, Failli P, Vizzutti F, Novo E, di Manzano C, Marra F, Loguercio C and Pinzani M. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J. Hepatol. 2009; 50 (6): 1102-11. [DOI:10.1016/j.jhep.2009.02.023]
19. Bosisio E, Benelli C and Pirola O. Effect of the flavanolignans of Silybum marianum L. on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. Pharmacol. Res. 1992; 25: 147-154. [DOI:10.1016/1043-6618(92)91383-R]
20. Feher J and Lengyel G. Silymarin in the treatment of chronic liver diseases: past and future. J. Clin. Exp. Med. 2009; 3 (3): 403-413. [DOI:10.1556/CEMED.3.2009.28519]
21. Blumenthal M. The complete commission German E monographs: Therapeutic guide to herbal medicines. American Botanical Council, Texas, USA, 1998.
22. Lee D Y-W and Liu Y. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A and isosilybin B. isolated from Silybum marianum (Milk Thistle). J. Nat. Prod. 2003; 66 (9): 1171-1174. [DOI:10.1021/np030163b]
23. Varma PN and Talwar SK. Chemical investigations of Silybum marianum. Planta Med. 1980; 38: 377. [DOI:10.1055/s-2008-1074893]
24. Brandon T, Gufford, Tyler N. Graf, Noemi D. Paguigan, Nicholas H. Oberlies and Mary F. Paine chemoenzymatic synthesis, characterization, and scale-up of milk thistle flavonolignan glucuronides. Drug Metab. Dispos. 2015; 43 (11): 1734-1743. [DOI:10.1124/dmd.115.066076]
25. Fallah Huseini H, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T and Raza M. The efficacy of Silybum marianum L. Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double‐blind, placebo‐controlled, clinical trial. Phytoter. Res. 2006; 20 (12): 1036-1039. [DOI:10.1002/ptr.1988]
26. Fallah Huseini H, Larijani B, Raajabipour B and Heshmat R. The effect of Silymarin on glycemic control of type II diabetes: A double blind randomized clinical trial. J. Med. Plants. 2005; 1 (13): 13-17.
27. Ramezani M, Azarabadi M, Abdi H, Baher G and Fallah Huseini H. The effects of Silybum marianum (L.) Gaertn.seed extract on glycemic control in type II diabetic patient's candidate for insulin therapy visiting endocrinology clinic in Baqiyatallah hospital in the years of 2006. J. Med. Plants. 2008; 2 (26): 79-84.
28. Mohammadi S, Fallah Huseini H, Afkhami Ardacani M, Salami M and Bolurani S. Effects of silymarin on insulin resistance and blood lipid profile in first-degree relatives of type 2 diabetic patients. J. Med. Plants. 2013; 2 (46): 170-176.
29. Ebrahimpour koujana S, Pourghassem Gargaria B, Mobasserib M, Valizadehc H and Asghari-Jafarabadi M. Effects of Silybum marianum (L.) Gaertn. (silymarin) extract supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: A randomized, triple-blind, placebo-controlled clinical trial. Phytomedicine. 2015; 22: 290-296. [DOI:10.1016/j.phymed.2014.12.010]
30. Velussi M, Cernigoi AM, De Monte A, Dapas F, Caffau C and Zilli M. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J. Hepatol. 1997; 26: 871-879. [DOI:10.1016/S0168-8278(97)80255-3]
31. Khalili N, Fereydoonzadeh R, Mohtashami R, Mehrzadi S, Heydari M and Fallah Huseini H. Silymarin, Olibanum, and Nettle, a mixed herbal formulation in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Evid.-based Complement. Alternat. Med. 2017; 22 (4): 603-608. [DOI:10.1177/2156587217696929]
32. Buzzetti E, Pinzani M and Tsochatzis E A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metab. Clin. Exp. 2016; 65 (8): 1038-1048. [DOI:10.1016/j.metabol.2015.12.012]
33. Araújo A R, Rosso N, Bedogni G, Tiribelli C and Bellentani S. Global epidemiology of non‐alcoholic fatty liver disease/non‐alcoholic steatohepatitis: What we need in the future. Liver Int. 2018; 38 (S1): 47-51. [DOI:10.1111/liv.13643]
34. Younossi Z M, Koenig A B, Abdelatif D, Fazel Y, Henry L and Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatol. 2016; 64 (1): 73-84. [DOI:10.1002/hep.28431]
35. Marjot T, Sbardella E, Moolla A, Hazlehurst J, Tan G, Ainsworth M, Cobbold J and Tomlinson J. Prevalence and severity of non‐alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital. Diabet. Med. 2018; 35 (1): 89-98. [DOI:10.1111/dme.13540]
36. Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, Subbarayan S, Webb A, Hecht J and Cusi K. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J. Clin. Endocrinol. Metab. 2015; 100 (6): 2231-2238. [DOI:10.1210/jc.2015-1966]
37. Wang L, Zhang J, Wang B, Zhang Y, Hong J, Zhang Y, Wang W and Gu W. New evidence for an association between liver enzymes and pancreatic islet β-cell dysfunction in young obese patients. Endocrine. 2013; 44(3): 688-95. [DOI:10.1007/s12020-013-9937-7]
38. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P and Rizzetto M. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatol. 2002; 35: 367-372. [DOI:10.1053/jhep.2002.30690]
39. Yao H, Qiao YJ, Zhao YL, Tao XF, Xu LN, Yin LH, and Peng JY. Herbal medicines and nonalcoholic fatty liver disease. World J. Gastroenterol. 2016; 22 (30): 6890-6905. [DOI:10.3748/wjg.v22.i30.6890]
40. Wah Kheong C, Nik Mustapha NR and Mahadeva S. A randomized trial of silymarin for the treatment of nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 2017; 15 (12): 1940-1949. [DOI:10.1016/j.cgh.2017.04.016]
41. Hashemi SJ, Hajiani E and Heydary SE. A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease. Hepat. Mon. 2009; 9 (4): 265-270.
42. Masoodi M, Rezadoost A, Panahian M and Vojdanian M. Effects of silymarin on reducing liver aminotransferases in patients with nonalcoholic fatty liver diseases. Govaresh. 2013; 18 (3): 181-185.
43. Solhi H, Ghahremani R, Kazemifar A M and Yazdi Z H. Silymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial. Caspian J. Intern. Med. 2014; 5 (1): 9-12.
44. Hajiaghamohammadi AA, Ziaee A, Oveisi S and Masroor H. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study. Hepat. Mon. 2012; 12 (8): 24-21. [DOI:10.5812/hepatmon.6099]
45. Aller R, Izaola O, Gómez S, Tafur C, González G, Berroa E, Mora N, González J and De Luis. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study. Eur. Rev. Med. Pharmacol. Sci. 2015; 19 (16): 3118-3124.
46. Han M, Wen P, Wen J-b and XU L-f. Clinical effect of silymarin combined with simvastatin on patients with nonalcoholic steatohepatitis. Chin. J. Liver Dis. (Electronic Version). 2011; 3: 15-18.
47. Loguercio C, Federico A, Trappoliere M, Tuccillo C, De Sio I, Di Leva A, Niosi M, D'Auria M V, Capasso R and Blanco C D V. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig. Dis. Sci. 2007; 52 (9): 2387- 2395. [DOI:10.1007/s10620-006-9703-2]
48. Loguercio C, Andreone P, Brisc C, Brisc MC, Bugianesi E, Chiaramonte M, Cursaro C, Danila M, de Sio I and Floreani A. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic. Biol. Med. 2012; 52 (9): 1658-1665. [DOI:10.1016/j.freeradbiomed.2012.02.008]
49. Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A and Del Vecchio Blanco C. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut. 2006; 55: 901-902. [DOI:10.1136/gut.2006.091967]
50. Yao J, Zhi M, Gao X, Hu P, Li C and Yang X. Effect and the probable mechanisms of silybinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver. Braz. J. Med. Biol. Res. 2013; 46 (3): 270-277. [DOI:10.1590/1414-431X20122551]
51. Malihi F, Hosseini-Tabatabaei A, Esmaily H, Khorasani R, Baeeri M and Abdollahi M. Improvement of inflammatory and toxic stress biomarkers by silymarin in a murine model of type one diabetes mellitus. Cent. Eur. J. Biol. 2009; 4 (3): 369-380. [DOI:10.2478/s11535-009-0014-4]
52. Elmarakby A A and Sullivan J C. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc. Ther. 2012; 30 (1): 49-59. [DOI:10.1111/j.1755-5922.2010.00218.x]
53. Fallah Huseini H, Asghari B, Asgarpanah J, Eghbali Zarch T and Babai Zarch A. Investigation of α-Amylase and α-Glucosidases inhibitory effects of Silybum marianum (L. Gaertn) seed extract in vitro. J. Med. Plants. 2012; 1 (41): 239-247.
54. Sales P M, Souza P M, Simeoni L A, Magalhães P O and Silveira D. α-Amylase inhibitors: a review of raw material and isolated compounds from plant source. J. Pharm. Pharm. Sci. 2012; 15 (1): 141-183. [DOI:10.18433/J35S3K]
55. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M and Manini R. Nonalcoholic fatty liver, steatohepatitis and the metabolic syndrome. Hepatol. 2003; 37 (4): 917-23. [DOI:10.1053/jhep.2003.50161]
56. Petta S, Muratore C and Craxi A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig. Liver Dis. 2009; 41 (9): 615-25. [DOI:10.1016/j.dld.2009.01.004]
57. Valenzuela A, Aspillaga M, Vial S and Guerra R. Selectivity of silymarin on the increase of the glutathione content in different tissues of the rat. Planta Medica. 1989; 55: 420-422. [DOI:10.1055/s-2006-962056]
58. Muzes G and Effect of the bioflavonoid silymarin on the in vitro activity and expression of super oxide dismutase (SOD) enzyme. Acta. Physiol. Hung. 1991; 78: 3-9.
59. Kropácová K, Misúrová E and Haková H. Protective and therapeutic effect of silymarin on the development of latent liver damage. Radiats. Biol. Radioecol. 1998; 38 (3): 411-5.
60. Kazazis C E, Evangelopoulos A A, Kollas A and Vallianou N G. The therapeutic potential of milk thistle in diabetes. Rev. Diabet. Stud. 2014; 11 (2): 167-74. [DOI:10.1900/RDS.2014.11.167]
61. Greenlee H, Abascal K, Yarne E and Ladas E. Clinical applications of Silybum marianum in oncology. Integr. Cancer Ther. 2007; 6 (2): 158-165. [DOI:10.1177/1534735407301727]
62. Giannola C, Buogo F, Forestiere G, Scaffidi L, Ferrigno V and Scaffidi A. A two-center study on the effects of silymarin in pregnant women and adult patients with so-called minor hepatic insufficiency. Clin. Ter. 1985; 114: 129-135.
63. Reyes H. The spectrum of liver and gastrointestinal disease seen in cholestasis of pregnancy. Gastroenterol. Clin. North Am. 1992; 21: 905-21.
64. Schleufe P and Seidel C. Amanita poisoning during pregnancy. Anasthesiol Intensivmed Notfallmed Schmerzther. 2003; 38 (11): 716-718.

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Journal of Medicinal Plants

Designed & Developed by : Yektaweb